All data generated or analysed during this study are included in this published article \[and its supplementary information files\]. All studies included in this systematic review have been previously published, and data are available from these publications. The reference list of his revision included doi (if available) for all published studies (included and excluded due to high risk of bias).

Introduction {#sec005}
============

The tumor necrosis factor alpha (TNF) antagonists target a cytokine that regulates inflammation in multiple diseases, including rheumatoid arthritis (RA) \[[@pone.0168005.ref001]\]. Evidence on the relative efficacy and safety of these medications is indirect and incomplete because no randomized controlled trials (RCTs) directly compare two or more TNF antagonists in RA patients \[[@pone.0168005.ref002]\]. Lack of efficacy and adverse effects are the most common reasons for discontinuing TNF antagonists \[[@pone.0168005.ref003]--[@pone.0168005.ref009]\], and therefore discontinuation risk is a good measure of the benefit-harm balance of these medications \[[@pone.0168005.ref010]\]. Hence, comparison of discontinuation risk of different TNF antagonists can help in treatment decisions, especially selection of an individual medication.

Since their introduction in the late 1990s, multiple observational studies have compared discontinuation of TNF antagonists, but the results were inconsistent \[[@pone.0168005.ref011]--[@pone.0168005.ref015]\] due to methodological and clinical heterogeneity. Methodological heterogeneity, defined as "variability in study design and risk of bias" \[[@pone.0168005.ref016]\], may be caused, for example, by differences in data collection. Clinical heterogeneity, defined as "variability in the participants, interventions and outcomes" \[[@pone.0168005.ref016]\], could be caused by differences in location and dates, or frequency of dose adjustments. A previous systematic review summarized hazard ratios for discontinuing TNF antagonists but failed to identify predictors of methodological or clinical heterogeneity \[[@pone.0168005.ref015]\]. The objective of this study is to investigate methodological and clinical heterogeneity in hazard ratios for discontinuing TNF antagonists in RA patients.

Methods {#sec006}
=======

Systematic literature search {#sec007}
----------------------------

Electronic databases (MEDLINE and EMBASE) to June 2015 were searched using the following strategy: (1) adalimumab.mp. (2) infliximab.mp (3) etanercept.mp. (4) tumour necrosis factor antagonists.mp. or Receptors, Tumour Necrosis Factor/ (5) 1 or 2 or 3 or 4 (6) (patient compliance or adherence or persistence or discontinuation or switching or treatment duration).mp. \[mp = ti, ab, sh, hw, tn, ot, dm, mf, ps, rs, nm, ui\] (7) rheumatoid arthritis.mp. or rheumatoid arthritis/ (8) 5 and 6 and 7. Additional studies were identified by reviewing reference lists of publications meeting the inclusion criteria and other published reviews.

Selection criteria for studies {#sec008}
------------------------------

We included studies of RA patients treated with infliximab, adalimumab, or etanercept that met the following criteria:

### Study design {#sec009}

Cohort studies with multiple TNF antagonists. RCTs were excluded due to differences between RA patients in RCTs and those treated in routine clinical practice \[[@pone.0168005.ref017]--[@pone.0168005.ref020]\]. Studies were selected regardless of the language and the type of publication (full articles, abstracts, or conference proceedings).

### Participants {#sec010}

RA patients, based on either the American College of Rheumatology diagnosis criteria \[[@pone.0168005.ref021],[@pone.0168005.ref022]\] or the clinical judgment of the care-providing physicians. Studies of multiple diseases were included only if the outcomes of interest were presented separately for RA.

### Types of interventions {#sec011}

First or second line treatments with infliximab, adalimumab, or etanercept selected by the care-providing physician and/or the patient. Studies of the newer TNF antagonists, such as certolizumab pegol or golimumab, were excluded due to shorter availability and fewer studies \[[@pone.0168005.ref015]\].

### Duration of follow-up {#sec012}

At least one year from treatment initiation.

### Outcome of interest {#sec013}

Pairwise hazard ratios for discontinuation: infliximab vs. etanercept, infliximab vs. adalimumab, and adalimumab vs. etanercept.

Data extraction {#sec014}
---------------

Two reviewers (AF and GG/DS) independently selected studies and extracted data. In case of a discrepancy, a decision was reached by consensus. Authors of published studies were contacted when reports were incomplete, confusing, or difficult to interpret. The reviewers extracted as-reported hazard ratios, and 95% confidence intervals (CI) or p-value. If the hazard ratio for a specific comparison was missing, we attempted to calculate it using indirect comparison methodology \[[@pone.0168005.ref023]\] or synthesis of estimates from subgroups. To prevent the use of duplicate or overlapping data from the same source, we selected a single hazard ratio from a fully-published manuscript with the largest population for each comparison and data source.

Risk of bias {#sec015}
------------

We identify two specific sources of bias in studies of discontinuation and included only studies with low risk of bias, defined as:

1.  The study outcome was discontinuing the individual medication or switching to a second biologic anti-rheumatic medication. Patients remaining on treatment at the end of the study period were censored.

2.  Discontinuation was not associated with the likelihood to be included in the study; i.e., new-user design without mandatory minimum treatment duration. In prevalent-user design, patients who started treatment before the study period are included only if they are still treated at the beginning of the study; hence, patients with longer use are overrepresented.

Statistical analysis {#sec016}
--------------------

Hazard ratios for discontinuation with 95% CI were combined using an inverse variance approach, and data were recorded on the natural logarithm scale \[[@pone.0168005.ref024]\]. We calculated random effect estimates \[[@pone.0168005.ref025]\] because substantial heterogeneity has previously been observed \[[@pone.0168005.ref011],[@pone.0168005.ref015]\].

In the absence of a definitive statistical test to assess whether a factor causes heterogeneity, we identified effect modifiers. We tested for the association between the effect size and clinical factors: continent, order of treatment, age, sex, and Disease Activity Score (DAS-28) as well as methodological factors: type of data and duration of follow-up. Categorical factors consisted of continent (Europe, Asia, or America), order of treatment (first or second line), and type of data (clinical charts, disease or drug registries, or administrative claim data). For these factors, we conducted between-subgroup I-square statistics, and estimated the significance using chi-squared test \[[@pone.0168005.ref026]\]. For continuous factors, i.e., age, sex, baseline DAS-28, and duration of follow-up, we conducted meta-regression \[[@pone.0168005.ref027]\] with a fixed effect model and weights based on the inverse of the variance of the logarithm of the hazard ratio. For factors that were reported as the average or the median of populations, we stratified the regression model by type of central measure. A significant association between a factor and the effect size was defined as a two-tailed p-value \<0.05 for both categorical and continuous variables. Analyses were conducted using the Review Manager (RevMan) statistical software (Version 5.3, The Nordic Cochrane Centre, The Cochrane Collaboration, Denmark) and SAS software package (Version 9.4, SAS Institute Inc., Cary, NC).

Results {#sec017}
=======

A total of 2,409 unique citations were identified and screened ([Fig 1](#pone.0168005.g001){ref-type="fig"}), and 24 unique studies were eligible for inclusion ([Table 1](#pone.0168005.t001){ref-type="table"}). Forty studies reported hazard ratios for discontinuing TNF antagonists but were excluded, most commonly because the study drugs were not compared ([S1 Table](#pone.0168005.s004){ref-type="supplementary-material"} in the on-line supporting information). Two of the studies were excluded due to high risk of bias \[[@pone.0168005.ref028],[@pone.0168005.ref029]\]. Three studies reported outcomes from the SSTAG/ARTIS Swedish registry \[[@pone.0168005.ref005],[@pone.0168005.ref030],[@pone.0168005.ref031]\], two studies from the Spanish BIOBADASER 2.0 registry or hospitals contributing to it \[[@pone.0168005.ref006],[@pone.0168005.ref032]\], two studies from the Italian Monitornet registry \[[@pone.0168005.ref033],[@pone.0168005.ref034]\], two studies from the American claim database MarketScan \[[@pone.0168005.ref035],[@pone.0168005.ref036]\], and three studies from the national insurance claim data or hospitals in South Korea \[[@pone.0168005.ref037],[@pone.0168005.ref038]\] ([Table 1](#pone.0168005.t001){ref-type="table"}).

10.1371/journal.pone.0168005.t001

###### Characteristics of eligible studies.

![](pone.0168005.t001){#pone.0168005.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                      Data source                                                                                                 Period                          RA diagnosis                                                                                                                    Type of users                                                                      Previous DMARDs                                                                                     Persistence/ discontinuation                                                                                                                                                                                                           N (INF, ADA, ETA)                                                                       Follow up
  ------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  Kristensen 2006 \[[@pone.0168005.ref039]\]                                     South Swedish Arthritis Treatment Group (SSATG), Sweden                                                     March 1999---December 2004      Clinical judgement by the treating physician. 98% fulfilled the ACR 1987 criteria                                               Biologics naive                                                                    ≥2, including MTX previously without satisfactory response                                          Registered prospectively, based on the judgement of the treating physician.                                                                                                                                                            1161 (721, 440)                                                                         Not reported

  Fernandez-Nebro 2007 \[[@pone.0168005.ref032]\]                                A tertiary care center, a structured clinical follow-up protocol, Spain                                     March 1999---January 2006       ACR criteria                                                                                                                    Anti-TNF-naive                                                                     ≥2, including MTX previously without satisfactory response                                          \"Definitive\"                                                                                                                                                                                                                         161 (60, 22[^a^](#t001fn001){ref-type="table-fn"}, 79)                                  Mean (STD) 20.6 (16.8) months; range 0.0--62.2; median 24

  Borah 2009 \[[@pone.0168005.ref040]\]                                          Claims data (I3 Innovus), a large managed health care plan, US                                              January 2005---December 2006    ≥1 medical claim with RA as the primary diagnosis prior to the index date                                                       ≥6 months without dispensing                                                       Not reported                                                                                        \>30-day medication-free gap or switching                                                                                                                                                                                              1230 (0, 527, 703)                                                                      12 months

  Du Pan 2009 \[[@pone.0168005.ref041]\]                                         Swiss Clinical Quality Management for Rheumatoid Arthritis (SCQM-RA) registry, Switzerland                  January 1997---December 2006    Not reported                                                                                                                    78% anti-TNF naive                                                                 Not reported                                                                                        \> 6 month medication-free gap                                                                                                                                                                                                         2364 (595, 882, 887)                                                                    Not reported

  Marchesoni 2009 \[[@pone.0168005.ref042]\]                                     LORHEN registry, Italy                                                                                      January 1999 --December 2001    ACR criteria                                                                                                                    First course in the registry                                                       ≥1 course of combination therapy, one of which should always be MTX without satisfactory response   Discontinuation due to clinical remission---censored                                                                                                                                                                                   1064 (519, 303, 242)                                                                    6--36 months of follow-up, or discontinued therapy within 6 months

  Hetland 2010 \[[@pone.0168005.ref043]\]                                        DANBIO registry, Denmark                                                                                    October 2000--3 April 2009      clinical judgement by the treating physician                                                                                    Not reported                                                                       ≥1 without satisfactory response                                                                    Not reported                                                                                                                                                                                                                           2326 (1134, 675, 517)                                                                   Median (IQR) for adalimumab, 20 months 7--39); etanercept, 21 months (9--42); infliximab, 16 months (5--36)

  Cho 2012 \[[@pone.0168005.ref037]\]                                            National Health Insurance (NHI) claim database, South Korea                                                 January 2007---December 2009    A diagnosis of RA (ICD10-M05 or M06)                                                                                            New-user design (washout period from January 2007 to June 2007 without anti-TNF)   Not reported                                                                                        \>14-week refill free gap Persistence = the number of days between the first and last refills                                                                                                                                          388(26[^b^](#t001fn002){ref-type="table-fn"}, 219, 143)                                 Not reported

  Gomez-Reino 2012 \[[@pone.0168005.ref006]\]                                    BIOBADASER 2.0, Spain                                                                                       February 2000 --December 2010   Not reported                                                                                                                    First treatment                                                                    Not reported                                                                                        Not reported                                                                                                                                                                                                                           2097 (1273, 761, 873)                                                                   First year

  Greenberg 2012, \[[@pone.0168005.ref044]\]                                     CORRONA registry, US                                                                                        February 2002---March 2008      Not reported                                                                                                                    \(1\) Biologics naive (2) First time switchers                                     Not reported                                                                                        Data was collected every 3 months. \" we used the visit dates of reported initiation and visit dates of reported discontinuation\"                                                                                                     \(1\) 1475 (535, 460,480)\                                                              Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           (2) 616 (166, 311, 139)                                                                 

  Soderlin 2012 \[[@pone.0168005.ref031]\]                                       South Swedish Arthritis Treatment Group (SSATG) biologics register, Sweden                                  March 1999---December 2005      A clinical diagnosis                                                                                                            First anti-TNF course                                                              MTX alone or in combination without any satisfactory response and/or intolerance                    Not reported                                                                                                                                                                                                                           534                                                                                     A minimum of 3.6 years

  Caporali 2013 \[[@pone.0168005.ref033]\] \[A\]                                 Monitornet database, Italy                                                                                  from January 2007               Not reported                                                                                                                    First course                                                                       Not reported                                                                                        Not reported                                                                                                                                                                                                                           1992(426, 685, 881)                                                                     Not reported

  Chen 2013 \[[@pone.0168005.ref045]\] \[A\]                                     National Health Insurance (NHI), Taiwan                                                                     Not reported                    Not reported                                                                                                                    Anti-TNF naïve                                                                     Not reported                                                                                        \>84-day refill free gap                                                                                                                                                                                                               4592 (0, 1982,2609)                                                                     First year

  Hishitani 2013 \[[@pone.0168005.ref046]\]                                      Osaka BiRD registry, Japan                                                                                  September 1999---April 2012     ACR criteria                                                                                                                    Biologics naive[^c^](#t001fn003){ref-type="table-fn"}                              ≥1                                                                                                  Discontinuation due to remission or miscellaneous reasons and missing data were treated as censored cases                                                                                                                              401[^d^](#t001fn004){ref-type="table-fn"} (103, 58, 143)                                Not reported

  Johnston 2013 \[[@pone.0168005.ref035]\] \[A\]                                 Truven Health MarketScan databases, US                                                                      January 2010---June 2011        Not reported                                                                                                                    Used at least one biologic prior to index                                          Not reported                                                                                        A 90-day medication-free gap or switching to another biologic                                                                                                                                                                          7515[^e^](#t001fn005){ref-type="table-fn"} (672, 1504, 1114)                            Not reported

  Scire 2013 \[[@pone.0168005.ref034]\]                                          Monitornet database, Italy                                                                                  January 2007---April 2012       Not reported                                                                                                                    Anti-TNF-naive                                                                     Failure                                                                                             Medication interruption ≥ 3 months. Persistence = the number of days between the first and last day of treatment                                                                                                                       2640 (718, 887, 1035)                                                                   Not reported

  Senabre-Gallego 2013 \[[@pone.0168005.ref047],[@pone.0168005.ref048]\] \[A\]   \"our local cohort\" Asociación para la Investigación en Reumatología de la Marina Baixa (AIRE-MB), Spain   January 2001---November 2011    Not reported                                                                                                                    Not reported                                                                       Not reported                                                                                        Not reported                                                                                                                                                                                                                           318 (97, 116, 105)                                                                      Not reported

  Fisher 2014 \[[@pone.0168005.ref049]\]                                         BC Ministry of Health databases, Canada                                                                     March 2001---December 2009      ≥2 outpatient at least 60 days apart or ≥1 inpatient diagnosis of RA (ICD-9 714.XX) the three years prior to TNF-b initiation   Biologics naive                                                                    Not reported                                                                                        ≥180 days medication-free gap or switching to another 'biologic'                                                                                                                                                                       2286 (620, 344, 1322)                                                                   Not reported

  Flouri 2014 \[[@pone.0168005.ref050]\]                                         Hellenic Registry of Biologic Therapies, Greece                                                             January 2004---April 2011       according to the treating physician                                                                                             79% anti-TNF naïve                                                                 ≥1                                                                                                  \"registered prospectively\"                                                                                                                                                                                                           1028 patients, 1297 courses (560, 435, 302)                                             The median (IQR) 3.0(1.2--6.2) years for infliximab, 2.9(1.1--5.9) years for adalimumab, and 2.9(1.1--5.0) years for etanercept.

  Frazier-Mironer 2014 \[[@pone.0168005.ref051],[@pone.0168005.ref052]\]         Medical charts, eight rheumatology centers, France                                                          March 2005---April 2011         1987 ACR criteria                                                                                                               \(1\) Biologics naïve (2) second anti-TNF medication                               Not reported                                                                                        The first definitive treatment interruption or last observation on treatment after initiation (exact time collected via the patient chart): indicated by the treating rheumatologist, or no consecutive re-introduction of treatment   \(1\) 706 (99, 203, 404) (2) 231 (20[^f^](#t001fn006){ref-type="table-fn"}, 105, 106)   2--6 years

  Kang 2014 \[[@pone.0168005.ref053],[@pone.0168005.ref054]\]                    Medical charts, Chonnam National University Hospital, Gwangju, South Korea                                  December 2002---November 2011   ACR criteria                                                                                                                    Anti-TNF naive                                                                     Not reported                                                                                        Not reported                                                                                                                                                                                                                           144 (22, 48, 39)                                                                        At least one year

  Lee 2014 \[[@pone.0168005.ref038]\] \[A\]                                      Health Insurance Review and Assessment Service, South Korea                                                 2006---December 2010            ≥2 prescriptions of DMARD under the diagnosis of RA                                                                             New-user design (washout period without DMARDs during 2006)                        Not reported                                                                                        Medication-free gap of \> half of the days supply of the previous prescription, or switching to other TNF inhibitors                                                                                                                   2203 (458, 1202, 543)                                                                   Not reported

  Neovius 2015, \[[@pone.0168005.ref005]\]                                       Swedish Biologics Register (ARTIS), Sweden                                                                  January 2003---December 2011    Assessment of the treating rheumatologists                                                                                      Anti-TNF-naive                                                                     Not reported                                                                                        As reported by the treating rheumatologist, due to any cause, except for pregnancy and remission. discontinuation                                                                                                                      2898                                                                                    Up to 5 years

  Johnston 2015 \[[@pone.0168005.ref055]\]                                       Truven Health MarketScan database, US                                                                       January 2010 --December 2011    ICD-9-CM codes recorded on medical claims between January 2009 and March 2012                                                   Previously used ≥1 other biologic                                                  Not reported                                                                                        ≥90 days Medication-free gap or switching to another biologic                                                                                                                                                                          9782[^g^](#t001fn007){ref-type="table-fn"} (922, 2179, 16750                            Not reported
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Patients treated with adalimumab were excluded due to the reduced sample size.

^b^ Patients treated with infliximab were excluded from analysis, since this medication was not available throughout the analysis period

^c^ Patients who started therapy before entering the registry were included.

^d^ Including 97 patients treated with tocilizumab.

^e^ Including patients treated with abatacept (1297), certolizumab (681), golimumab (951), and rituximab (622).

^f^ Patients treated with infliximab were excluded from analysis of second anti-TNF due to small numbers.

^g^ Including patients treated with abatacept (1759), certolizumab (962), golimumab (1195), and tocilizumab (1090)

\[A\] Abstract, ACR American Collage of Rheumatology, DMARDs Disease Modifying Anti-Rheumatic Drugs, ICD-9 the International Classification of Diseases Ninth Revision, ICD-9-CM the International Classification of Diseases Ninth Revision Clinical Modification, ICD10 the International Classification of Diseases Tenth Revision, IQR Interquartile Range, MTX Methotrexate, STD Standard Deviation, TNF Tumor Necrosis Factor alpha, US United Stated of America

![QUOROM flow chart.\
^1^ SSATG is part of ARTIS, data were overlapping with Neovius 2015. ^2^ Carlos Haya hospital is included in BIOBADASER 2.0, data were overlapping with Gomez-Reino 2012. ^3^ Data from South Korea NIH, also known as Health Insurance Review and Assessment Service, were included in Lee 2014. ^4^ Data from MonitorNet were included in Scire 2013. ^5^ Data from MarketScan were included in Johnstone 2015.](pone.0168005.g001){#pone.0168005.g001}

Fifteen studies (20,796 patients) from unique data sources compared infliximab and adalimumab with the overall pooled hazard ratio of 1.08 (95% C\] 0.92--1.27) ([S1 Fig](#pone.0168005.s001){ref-type="supplementary-material"}). Fifteen studies (23,671 patients) from unique data sources compared infliximab and etanercept with the overall pooled hazard ratio of 1.22 (1.00--1.49) ([S2 Fig](#pone.0168005.s002){ref-type="supplementary-material"}). Seventeen studies (27,799 patients) from different data sources showed higher risk of discontinuing adalimumab compared with etanercept and the overall pooled hazard ratio was 1.17 (1.08--1.27) ([S3 Fig](#pone.0168005.s003){ref-type="supplementary-material"}). There was significant heterogeneity between studies for all three comparisons, with I square statistics of 86%, 92%, and 56%, respectively.

Assessment of methodological and clinical heterogeneity is presented in [Table 2](#pone.0168005.t002){ref-type="table"}. In analysis of categorical factors, effect modifications of the type of data ([Fig 2](#pone.0168005.g002){ref-type="fig"}), location ([Fig 3](#pone.0168005.g003){ref-type="fig"}), and order of treatment ([Fig 4](#pone.0168005.g004){ref-type="fig"}) was observed in comparisons of infliximab with adalimumab or etanercept, but not comparing adalimumab with etanercept. This effect modification was expressed as I squared statistics of 69.1--92.7%, with p-value \<0.05 in Chi squared test. These percentages could be interested as following: 69.1--92.7% of variation across subgroups in each comparison is due to heterogeneity rather than chance. We also noticed that in all comparisons, not all subgroup hazard ratios reach statistical significance level and in most cases a residual within subgroup heterogeneity was observed. For example, in analysis of type of data ([Fig 2](#pone.0168005.g002){ref-type="fig"}), when comparing infliximab with etanercept, we observed significant heterogeneity between the three subgroups compared: studies based on clinical charts, those conducted on registries and analyses of claim data (I square statistics of 69.1%). Only studies conducted on registries had a significant pooled hazard ratio of 1.49 (95% CI 1.23--1.81), but they also consisted the largest subgroup. A reversed direction of hazard ratio was estimated in two studies based on clinical charts and three analyses of claim data, i.e., lower risk of discontinuing infliximab, but these polled estimates did not reach significance level. We noticed residual heterogeneity within each subgroup: clinical chart, registries, and claim data.

10.1371/journal.pone.0168005.t002

###### Assessment of heterogeneity: association between study design and patient characteristics and effect sizes.

![](pone.0168005.t002){#pone.0168005.t002g}

                                 Factor tested and statistics                                                         Infliximab vs. adalimumab   Infliximab vs. etanercept   Adalimumab vs. etanercept
  ------------------------------ ------------------------------------------------------------------------------------ --------------------------- --------------------------- ---------------------------
  Clinical heterogeneity         Continent I^2^, p-value                                                              82.7, \<0.0001              91.3, \<0.0001              0, 039
                                 Order of treatment I^2^, p-value                                                     77.5, 0.03                  92.1, 0.004                 0, 0.49
                                 Age (infliximab users), regression parameter (standard error), p-value               0.015 (0.032), 0.66         0.006 (0.029), 0.8          
                                 Age (adalimumab users), regression parameter (standard error), p-value               0.037 (0.034), 0.30         n/a                         0.008 (0.022), 0.72
                                 Age (etanercept users), regression parameter (standard error), p-value               n/a                         0.142 (0.085), 0.14         -0.006 (0.022), 0.78
                                 Sex (infliximab users), regression parameter (standard error), p-value               0.77 (0.532), 0.18          4.668 (1.49), 0.01          n/a
                                 Sex (adalimumab users), regression parameter (standard error), p-value               0.757 (0.443), 0.12         n/a                         -0.140 (0.398), 0.73
                                 Sex (etanercept users), regression parameter (standard error), p-value               n/a                         2.054 (0.929), 0.05         -0.186 (0.486), 0.71
                                 Baseline DAS (infliximab users), regression parameter (standard error), p-value      0.055 (0.084), 0.54         -0.234 (0.338), 0.51        n/a
                                 Baseline DAS (adalimumab users), regression parameter (standard error), p-value      0.051 (0.072), 0.51         n/a                         -0.088 (0.165), 0.61
                                 Baseline DAS (etanercept users), regression parameter (standard error), p-value      n/a                         -0.225 (0.266), 0.43        -0.145 (0.193), 0.48
  Methodological heterogeneity   Type of data I^2^, p-value                                                           79.4, 0.008                 69.1, 0.04                  11.6, 0.32
                                 Duration of follow-up, regression parameter per 10 years (standard error), p-value   -0.004 (0.001), 0.62        -0.033 (0.03), 0.30         -0.001 (0.004), 0.90

P-value \<0.05 represents a significant effect of the factor tested on the hazard ratio in the individual comparison (between-subgroup I-square statistics \[[@pone.0168005.ref026]\] and p-value of chi-squared test for categorical factors, and meta-regression \[[@pone.0168005.ref027]\] with a fixed effect model and weights based on the inverse of the variance of the logarithm of the hazard ratio for continuous factors).

DAS- disease activity score; n/a--not applicable

![Assessment of methodological heterogeneity: subgroup analysis for type of data.](pone.0168005.g002){#pone.0168005.g002}

![Assessment of clinical heterogeneity: subgroup analysis for location.](pone.0168005.g003){#pone.0168005.g003}

![Assessment of clinical heterogeneity: subgroup analysis for order of treatment.](pone.0168005.g004){#pone.0168005.g004}

In analysis of continuous factors ([Table 2](#pone.0168005.t002){ref-type="table"}), the proportion of female patients using infliximab modified the hazard ratio in comparison of infliximab with etanercept. However, in the presence of multiple comparisons and in the absence of similar effect of the proportion of female patients using etanercept we discarded this finding. Finally, duration of follow up, age, and baseline DAS-28 did not modify the hazard ratios ([Table 2](#pone.0168005.t002){ref-type="table"}).

Discussion {#sec018}
==========

This review explored sources of clinical and methodological heterogeneity in studies comparing discontinuation of TNF antagonists in RA patients. The type of data (i.e. charts, registries, or claims) modified the effect size in comparisons of infliximab with etanercept or adalimumab. However, this factor was not responsible for all the heterogeneity. Different types of data are susceptible to different types of biases. Registries are susceptible to selection bias caused by the volunteer enrollment and data collection \[[@pone.0168005.ref056]\]. Administrative data are susceptible to confounding due to the absence of clinical variables and exposure ascertainment bias because of the uncertainty whether patients who refilled the medication actually used it. Type of data also determines how the outcome, discontinuation, is defined. In analysis of registries or medical charts, discontinuation is recorded by physicians, either during a routine visit or in real-time. In analysis of administrative data, discontinuation is usually ascertained using prescription-refill analysis and applying grace periods \[[@pone.0168005.ref057]\]. Comparisons of discontinuing TNF antagonists are especially sensitive to these differences in outcome definition because of the intermittent dosing schedules and different lengths of dose interval for different medications. Comparisons of infliximab were more sensitive to the data source probably because it has a significantly longer dose interval than adalimumab and etanercept.

A second hazard modifier is location. In European countries, the risk of discontinuing etanercept and adalimumab is lower compared to infliximab, but in America, patients on infliximab had lower discontinuation risk compared to adalimumab and similar risk as patients treated with etanercept. In a previous review reported similar proportions of patients from European and non-European countries who discontinued any TNF antagonists \[[@pone.0168005.ref015]\], but the results were not presented separately for each individual medication. Souto et al \[[@pone.0168005.ref015]\] failed to determine whether these findings are constant across different medications.

Hazard ratio estimates were also modified by the order of treatment (first or second line) in comparisons of infliximab with adalimumab or etanercept. However, in these comparisons the only two studies that reported hazard ratios for second line treatment were American studies Therefore, we cannot rule out that the modification observed is related to location and not to order of treatment.

Age, sex, baseline disease activity score (DAS), and duration of follow-up did not modify the hazard ratios. The absence of modification by baseline DAS opposes the hypothesis by Greenberg 2014 \[[@pone.0168005.ref058]\] that the difference in estimates between American and European studies is caused by differences in disease severity.

The results of this review question the reliability of hazard ratios for discontinuing TNF antagonists. Specifically, the residual heterogeneity within subgroups may indicate that stable results cannot be duplicated by different researchers nor can conclusive scientific findings be obtained. Alternately, researchers may not be measuring the same outcome because different types of data, and possibly different definitions of discontinuation, modified the hazard ratios. Standardization of methodological approaches may help achieving the requisite reliability.

There are several limitations to our study. First, we were unable to adequately assess risk of bias in the absence of a specific evaluation tool for discontinuation studies. Available tools for observational studies, such as Newcastle-Ottawa scale \[[@pone.0168005.ref059]\], do not assess relevant items such as new-user design and ascertainment of discontinuation. The other tools, e.g., STROBE statement \[[@pone.0168005.ref060]\], assess the quality of reporting and not the risk of bias. Second, in the absence of a statistical test to determine causes of heterogeneity between studies, we could only assess effect modification. Last, we found significant residual heterogeneity within many of the subgroups and therefore pooled estimates were impossible to interpret.

This review had several strengths including the wide scope: no temporal or linguistic constraints. Second, to minimize bias, this review included only studies reporting adjusted hazard ratios for discontinuation. Earlier systematic reviews summarized proportions of discontinuation for each TNF antagonist individually \[[@pone.0168005.ref014],[@pone.0168005.ref015]\]. Because these proportions were crude estimates from observational data, comparisons between medications were most likely confounded. Last, we identified two major risks of bias in discontinuation studies and applied them in study selection.

Conclusions {#sec019}
===========

Substantial heterogeneity was found in studies estimating head-to-head hazard ratios for discontinuing TNF antagonists in RA patients due to differences in type of data, location, and order of treatment. The heterogeneity observed shows that stable results have not been duplicated by different researchers and conclusive scientific findings cannot be obtained by pooling results.
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